MYMETICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 USD | -96.16% |
|
-.--% | -99.69% |
| Sales 2021 | 430K 458K | Sales 2022 | 1.03M 1.09M | Capitalization | 8.51M 9.06M |
|---|---|---|---|---|---|
| Net income 2021 | -4M -4.26M | Net income 2022 | -4M -4.26M | EV / Sales 2021 | 177 x |
| Net Debt 2021 | 67.1M 71.42M | Net Debt 2022 | 71.68M 76.3M | EV / Sales 2022 | 78 x |
| P/E ratio 2021 |
-1.86
x | P/E ratio 2022 |
-1.77
x | Employees | 2 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 48.72% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -96.16% | ||
| 3 months | -92.31% | ||
| 6 months | -99.71% | ||
| Current year | -99.69% |
Current year
0.01
0.26
1 year
0.0156.60
3 years
0.01239.80
5 years
0.01380.00
10 years
0.01380.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 09-06-30 | |
Mario Amacker
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Staehelin
BRD | Director/Board Member | 76 | 07-07-01 |
Ulrich Burkhard
BRD | Director/Board Member | 63 | 12-03-22 |
Marcel B. Rüegg
BRD | Director/Board Member | - | 23-01-15 |
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
| 1st Jan change | Capi. | |
|---|---|---|
| -99.69% | 1.52K | |
| +2.49% | 96.73B | |
| -0.23% | 21.31B | |
| -16.61% | 21.21B | |
| -4.97% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- MYMX Stock
